Monte Rosa Therapeutics' CEO will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 3, 2024.
Quiver AI Summary
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel molecular glue degrader (MGD) medicines, announced that CEO Markus Warmuth will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York on December 3, 2024. The event will be available for live streaming on the company's website, with an archived version accessible for 30 days afterward. Monte Rosa is known for its QuEEN™ discovery engine, which uses advanced technology to create highly selective MGDs for serious conditions in oncology, autoimmune diseases, and more. The company has partnerships with Novartis and Roche to progress their innovative therapies.
Potential Positives
- Participation of CEO Markus Warmuth in a prominent healthcare conference enhances company visibility and credibility in the biotech industry.
- Webcast accessibility indicates transparency and engagement with investors and stakeholders.
- Company's focus on innovative molecular glue degrader (MGD) technologies positions it at the forefront of biotechnology advancements, potentially attracting interest from investors and partners.
- Strategic partnerships with Novartis and Roche highlight Monte Rosa's strong collaborative efforts and potential for impactful drug development.
Potential Negatives
- Participation in only a fireside chat at a major healthcare conference may signal a lack of significant new developments or announcements, potentially leading to skepticism among investors regarding the company's progress.
FAQ
What is the date and time of Markus Warmuth's fireside chat?
Markus Warmuth's fireside chat is scheduled for December 3, 2024, at 3:30 p.m. ET.
Where can I access the webcast of the event?
The webcast will be available in the “Events” section of Monte Rosa’s website at ir.monterosatx.com.
How long will the archived version of the fireside chat be available?
An archived version of the fireside chat will be accessible for 30 days following the presentation.
What type of therapies does Monte Rosa Therapeutics focus on?
Monte Rosa Therapeutics develops molecular glue degrader (MGD) therapies primarily for oncology, autoimmune, and inflammatory diseases.
What is the QuEEN™ discovery engine?
The QuEEN™ discovery engine is Monte Rosa's platform that combines AI-guided chemistry with proteomics to design selective MGDs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GLUE Insider Trading Activity
$GLUE insiders have traded $GLUE stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $GLUE stock by insiders over the last 6 months:
- VENTURE CAPITAL VI, L.P. VERSANT has traded it 7 times. They made 0 purchases and 7 sales, selling 1,857,674 shares.
- EDMUND DUNN (Principal Accounting Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 2,817 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$GLUE Hedge Fund Activity
We have seen 54 institutional investors add shares of $GLUE stock to their portfolio, and 22 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AVORO CAPITAL ADVISORS LLC added 1,255,236 shares (+27.7%) to their portfolio in Q3 2024
- PRICE T ROWE ASSOCIATES INC /MD/ added 623,554 shares (+10.4%) to their portfolio in Q3 2024
- BLACKROCK, INC. added 541,398 shares (+22.9%) to their portfolio in Q3 2024
- PARKWOOD LLC added 426,620 shares (+inf%) to their portfolio in Q3 2024
- IKARIAN CAPITAL, LLC added 311,593 shares (+inf%) to their portfolio in Q3 2024
- SPHERA FUNDS MANAGEMENT LTD. removed 256,897 shares (-68.5%) from their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC added 197,247 shares (+23.3%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York, NY on Tuesday, December 3, 2024, at 3:30 p.m. ET.
A webcast of the fireside chat will be accessible via the “Events” section of Monte Rosa’s website at ir.monterosatx.com , and an archived version will be made available for 30 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
[email protected]
Media
Cory Tromblee, Scient PR
[email protected]
